Showing 1 to 15 of 33 results for alzheimer's disease
This guideline covers diagnosing and managing dementia (including Alzheimer’s disease). It aims to improve care by making recommendations on training staff and helping carers to support people living with dementia.
Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.
In development [GID-TA11220] Expected publication date: 17 July 2024
In development [GID-TA11221] Expected publication date: 11 September 2024
This guideline covers providing brief advice on physical activity to adults in primary care. It aims to improve health and wellbeing by raising awareness of the importance of physical activity and encouraging people to increase or maintain their activity level.
This guideline covers mid-life approaches to delay or prevent the onset of dementia, disability and frailty in later life. The guideline aims to increase the amount of time that people can be independent, healthy and active in later life.
NICE's impact on preventing or delaying the onset of dementia
impact of treating Alzheimer 8217;s disease on mortality and institutionalisation and to assess the relationship between...
Awaiting development [GID-TA11072] Expected publication date: TBC
Awaiting development [GID-TA11379] Expected publication date: TBC
on the effects of treating people with Alzheimer 8217;s disease on both short term and long term outcomes...
NICE's HTA Lab enables us to develop creative solutions to complex problems in health technology assessment.
Summary of the evidence on melatonin for treating sleep disorders in adults who are blind
How NICE recommendations are being used to improve outcomes in priority areas of dementia care